Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.

232.65 2.70 −1.15%
Market cap
$34.8B
P/E
41.0×
Fwd P/E
31.5×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

12.75 19.93 19.61 38.04
P/S ratio
2.04 2.61 2.72 3.18
P/FCF ratio
9.08 12.77 11.24 12.56
P/Operating CF
16.14 50.37 41.81 71.09
P/B ratio
1.13 1.41 1.45 1.69
Price to Tangible BV
8.61 9.97 8.68 0.00
EV/Sales
2.27 2.86 2.92 3.78
EV/EBITDA
7.23 9.62 9.57 14.71
EV/Operating CF
9.32 12.82 11.19 13.17
EV/FCF
10.11 13.99 12.07 14.93
Quick Ratio
1.62 1.54 1.88 0.81
Current Ratio
2.72 2.68 3.06 1.87
Net Debt/EBITDA
2.72 5.84 2.83 10.18
Debt/Assets
21.52% 21.35% 21.33% 22.72%
Debt/Equity
0.35 0.34 0.34 0.39
Asset Turnover
0.35 0.34 0.35 0.33
Operating CF/Net income
2.73 (10.47) 2.02 4.60
Capex/Depreciation
(0.20) (0.19) (0.16) (0.40)
Research and Development Expense of Revenue
17.21% 22.35% 21.75% 19.36%
Selling, General and Administrative Expense of Revenue
23.47% 29.94% 24.51% 25.94%
Intangible Assets out of Total Assets
0.54 0.53 0.53 0.64
Share Based Compensation of Revenue
2.97% 2.61% 3.39% 2.83%
Graham Net Nets
(0.10) (0.09) (0.06) (0.19)
Graham Number
175.25 157.35 163.27 127.71
Earnings Yield
7.85% 5.02% 5.10% 2.63%
Free Cash Flow Yield
11.02% 7.83% 8.90% 7.96%
Revenue per Share
17.29 15.56 16.83 18.52
Operating CF per Share
8.68 3.49 4.39 3.04
Capex per Share
(0.35) (0.41) (0.35) (1.19)
Free Cash Flow per Share
8.33 3.08 4.04 1.85
Cash per Share
27.02 26.05 29.09 8.70
Shareholders Equity per Share
124.20 124.62 126.71 127.61
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
124.20 124.62 126.71 127.61
Free Cash Flow
1,221.00 451.70 594.30 273.00
Working Capital
5,646.60 5,624.70 6,191.50 3,388.60
Capital Expenditures
(51.50) (60.20) (51.20) (175.90)
Net Current Asset Value
(2,063.40) (2,208.60) (1,641.00) (5,932.90)
EV/EBIT
10.37 15.17 15.42 30.63
Capex to Sales
0.02 0.03 0.02 0.06
Price to Operating Income
9.31 13.85 14.36 25.78
Other line items
Average Receivables
1,455.15 1,373.60 1,682.85 1,754.90
Average Payables
417.90 428.10 375.00 406.15
Average Inventory
2,339.30 2,314.30 2,111.45 2,329.30
Average Assets
28,760.35 28,744.40 28,758.10 30,208.40
Average Common Equity
17,283.20 17,486.40 17,815.20 18,241.00

Fold the line items

Columns are period end dates